Immunome (IMNM)
(Delayed Data from NSDQ)
$14.66 USD
+0.50 (3.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $14.64 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Immunome, Inc. (IMNM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.40 | $38.00 | $24.00 | 121.75% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Immunome, Inc. comes to $31.40. The forecasts range from a low of $24.00 to a high of $38.00. The average price target represents an increase of 121.75% from the last closing price of $14.16.
Analyst Price Targets (5 )
Broker Rating
Immunome, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/IMNM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/31/2024 | Piper Sandler | Biren Amin | Not Available | Strong Buy |
4/15/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
4/1/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
1/29/2024 | SVB Securities | Andrew Berens | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $31.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.38 |